Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie’s Cancer Expansion Is Paying Off

Executive Summary

Label-expansion plans for Imbruvica, along with approvals for Venclexta and Rova-T headline AbbVie's efforts to build a substantial cancer portfolio. The BTK inhibitor was AbbVie's second-best seller in 2016, passing HCV combo Viekira Pak.

You may also be interested in...



Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.

AbbVie's Gonzalez Calls Break-Up Proposal Rational, But Premature

CEO says the idea of forming one company around Humira and its earnings and another around the R&D pipeline holds merit but he wants to wait to see the outcome of US tax reform, which could address some of AbbVie's issues.

Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy

The failure of veliparib in Phase III studies of squamous NSCLC and triple-negative breast cancer is a blow for AbbVie's oncology pipeline, but may not have implications for other PARP inhibitors in new tumor types.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098130

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel